Wednesday, June 10, 2026
🇺🇸 FDA

pharma

Biofrontera Bioscience

Biofrontera Bioscience GmbH

Biofrontera Bioscience patent portfolio — 13 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

EU HQ
EMA registrant Type
Company details
Status
Public
HQ
EU
Programs
0
Drugs
0
Patents
13
Patents News & analysis
Intelligence · Patents

Biofrontera Bioscience patents

13 pharmaceutical patents indexed for Biofrontera Bioscience. 0 expire within 24 months.

Biofrontera Bioscience has 13 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

13 patents

Patent portfolio

  1. US 20260108463

    NANOEMULSION FORMULATION WITH IMPROVED TACROLIMUS STABILITY AND SKIN PENETRATION

    Expires Wed Apr 18 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 2024335360

    PRESSURIZED NANOEMULSION

    Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. WO 2024209065

    NANOÉMULSION SOUS PRESSION

    Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. WO 2024209064

    NANOÉMULSION SANS PROPYLÈNE GLYCOL

    Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 2024335380

    NANOEMULSION WITHOUT PROPYLENE GLYCOL

    Expires Wed Oct 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 2021315993

    PHOTODYNAMIC THERAPY COMPRISING TWO LIGHT EXPOSURES AT DIFFERENT WAVELENGTHS

    Expires Wed Oct 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. WO 2014117863

    FORMES POLYMORPHES DE SELS D'ADDITION D'ACIDE DE THIOXANTHÈNE-9-YLIDÈNE-1-MÉTHYLPIPÉRIDINES UTILISÉS COMME COMPOSÉS ANTIMIGRAINEUX

    Expires Wed Aug 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. DE 202010004750

    Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut

    Expires Mon Oct 06 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. EP 1938801

    Nanoemulsion

    Expires Tue Jun 27 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. EP 1655027

    Verwendung von 9-(N-methyl-piperidyliden-4)-thioxanthene zur Behandlung von pulmoler Hypertension und Migräne

    Expires Tue May 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  11. EP 1477166

    Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis

    Expires Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  12. EP 1255725

    5-AMINOLÄVULINSÄURE-FORMULIERUNG IN NICHTWÄSSRIGEN LÖSUNGSMITTELN

    Expires Tue Nov 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  13. AU 1271000

    Nano-emulsion of 5-aminolevulinic acid

    Expires Sun May 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many patents does Biofrontera Bioscience have?

13 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Biofrontera Bioscience patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.